Novo Nordisk Wegovy lowered liver fat to normal in 88.5% of patients

Novo Nordisk reported post hoc STEP UP data: in 26 adults with excess liver fat at baseline, 88.5% reached below 5% liver fat after 72 weeks of Wegovy (semaglutide 7.2/2.4 mg). Mean liver fat fell from 8.8% to 3.1% in 55 MRI-assessed participants.